Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | R330W |
Impact List | missense |
Protein Effect | no effect - predicted |
Gene Variant Descriptions | FGFR2 R330W lies within Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). R330W results in proliferation similar to wild-type Fgfr2 in a competition assay and transformation activity similar to wild-type in cultured cells (PMID: 34272467), and therefore, is predicted to have no effect on Fgfr2 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR2 mutant FGFR2 R330W |
Transcript | NM_000141.5 |
gDNA | chr10:g.121517415G>A |
cDNA | c.988C>T |
Protein | p.R330W |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017015925.3 | chr10:g.121515126_121515128delAGAinsTGG | c.988_990delAGAinsTGG | p.R330W | RefSeq | GRCh38/hg38 |
XM_017015924 | chr10:g.121515126_121515128delTCTinsCCA | c.988_990delAGAinsTGG | p.R330W | RefSeq | GRCh38/hg38 |
XM_006717711 | chr10:g.121515207_121515209delTCGinsCCA | c.988_990delCGAinsTGG | p.R330W | RefSeq | GRCh38/hg38 |
XM_024447890.2 | chr10:g.121515207_121515209delCGAinsTGG | c.988_990delCGAinsTGG | p.R330W | RefSeq | GRCh38/hg38 |
XM_017015924.2 | chr10:g.121515126_121515128delAGAinsTGG | c.988_990delAGAinsTGG | p.R330W | RefSeq | GRCh38/hg38 |
NM_001320658.2 | chr10:g.121517415G>A | c.988C>T | p.R330W | RefSeq | GRCh38/hg38 |
XM_017015925.2 | chr10:g.121515126_121515128delAGAinsTGG | c.988_990delAGAinsTGG | p.R330W | RefSeq | GRCh38/hg38 |
XM_024447891.2 | chr10:g.121515131G>A | c.988C>T | p.R330W | RefSeq | GRCh38/hg38 |
XM_017015922 | chr10:g.121515207_121515209delTCGinsCCA | c.988_990delCGAinsTGG | p.R330W | RefSeq | GRCh38/hg38 |
NM_000141 | chr10:g.121517415G>A | c.988C>T | p.R330W | RefSeq | GRCh38/hg38 |
XM_024447890.1 | chr10:g.121515207_121515209delCGAinsTGG | c.988_990delCGAinsTGG | p.R330W | RefSeq | GRCh38/hg38 |
NM_001144917 | chr10:g.121503893T>A | c.988A>T | p.R330W | RefSeq | GRCh38/hg38 |
XM_017015925 | chr10:g.121515126_121515128delTCTinsCCA | c.988_990delAGAinsTGG | p.R330W | RefSeq | GRCh38/hg38 |
NM_001144917.2 | chr10:g.121503893T>A | c.988A>T | p.R330W | RefSeq | GRCh38/hg38 |
NM_001320658 | chr10:g.121517415G>A | c.988C>T | p.R330W | RefSeq | GRCh38/hg38 |
XM_024447891.1 | chr10:g.121515131G>A | c.988C>T | p.R330W | RefSeq | GRCh38/hg38 |
XM_017015924.3 | chr10:g.121515126_121515128delAGAinsTGG | c.988_990delAGAinsTGG | p.R330W | RefSeq | GRCh38/hg38 |
NM_000141.4 | chr10:g.121517415G>A | c.988C>T | p.R330W | RefSeq | GRCh38/hg38 |
NM_000141.5 | chr10:g.121517415G>A | c.988C>T | p.R330W | RefSeq | GRCh38/hg38 |
XM_006717712 | chr10:g.121515131G>A | c.988C>T | p.R330W | RefSeq | GRCh38/hg38 |
XM_024447888.1 | chr10:g.121515207_121515209delCGAinsTGG | c.988_990delCGAinsTGG | p.R330W | RefSeq | GRCh38/hg38 |
XM_024447888.2 | chr10:g.121515207_121515209delCGAinsTGG | c.988_990delCGAinsTGG | p.R330W | RefSeq | GRCh38/hg38 |
NM_001144917.1 | chr10:g.121503893T>A | c.988A>T | p.R330W | RefSeq | GRCh38/hg38 |
NM_001320658.1 | chr10:g.121517415G>A | c.988C>T | p.R330W | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 R330W | Advanced Solid Tumor | predicted - sensitive | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 R330W were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 R330W | Advanced Solid Tumor | predicted - sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 R330W were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 R330W | Advanced Solid Tumor | predicted - resistant | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 R330W were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467). | 34272467 |
FGFR2 R330W | Advanced Solid Tumor | predicted - sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 R330W were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 R330W | Advanced Solid Tumor | predicted - sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 R330W were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 R330W | Advanced Solid Tumor | predicted - sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 R330W were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 R330W | Advanced Solid Tumor | predicted - sensitive | E7090 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 R330W were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |